Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
9.08
0.00 (0.00%)
Aug 14, 2026, 12:53 PM EDT - Market open
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
121
Market Cap
973.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 8.09M | -5.53M | -40.57% |
| Dec 31, 2021 | 13.62M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 450.89M |
| Geron | 204.56M |
| Arbutus Biopharma | 181.72M |
| Wave Life Sciences | 65.37M |
| Lexicon Pharmaceuticals | 41.47M |
| Omeros | 38.42M |
| Janux Therapeutics | 24.00M |
| Odyssey Therapeutics | 99.00K |
SLDB News
- 7 days ago - Solid Biosciences reports Q2 EPS (38c), consensus (47c) - TheFly
- 7 days ago - Solid Biosciences files automatic mixed securities shelf - TheFly
- 8 days ago - Solid Biosciences Quarterly report: Q2 2026 - Filings
- 8 days ago - Solid Biosciences Earnings release: Q2 2026 - Filings
- 2 months ago - Solid Biosciences Transcript: AGM 2026 - Transcripts
- 2 months ago - Solid Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Solid Biosciences Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Solid Biosciences price target raised to $25 from $20 at H.C. Wainwright - TheFly